aTyr Pharma to Present at March Investor Conferences
Details of the presentations appear below:
Conference: 35th Annual
Format: Fireside Chat
Conference: Oppenheimer 33rd Annual Healthcare Conference
Format: Corporate Presentation
In addition to the presentations, company management will be available to participate in one-on-one meetings with investors who are registered attendees of the conferences. A webcast and replay of the Corporate Presentation will be available on the Investor’s section of the company’s website at www.atyrpharma.com. For more information, please contact firstname.lastname@example.org.
aTyr is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr’s primary focus is efzofitimod, a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to downregulate immune engagement in fibrotic lung disease. For more information, please visit www.atyrpharma.com.
Director, Investor Relations and Corporate Communications
Source: aTyr Pharma, Inc.